2 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Flame Biosciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors 1 mg/kg IV FL-301, 3 mg/kg IV FL-301, 10 mg/kg IV FL-301 - Pancreas Cancer, Gastric Cancer | Phase 1 / Phase 2 | Withdrawn | Flame Biosciences | 2022-01-01 | 2022-02-07 | |
| FL-101 in Surgically Resectable Non-Small Cell Lung Cancer FL-101, Nivolumab, Placebo - Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Flame Biosciences | 2021-08-25 | 2022-01-11 |
Carcinoma, Non-Small-Cell Lung (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Nivolumab (1)